Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants

Min Shi Lee; David P. Greenberg; Sylvia H. Yeh; Ram Yogev; Keith S. Reisinger; Joel I. Ward; Mark M. Blatter; Iksung Cho; Sandra J. Holmes; Julie M. Cordova; Marilyn J. August; Wendy Chen; Harshvardhan B. Mehta; Kathleen L. Coelingh; Paul M. Mendelman

doi:10.1086/323150

Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants

Min Shi Lee, David P. Greenberg, Sylvia H. Yeh, Ram Yogev, Keith S. Reisinger, Joel I. Ward, Mark M. Blatter, Iksung Cho, Sandra J. Holmes, Julie M. Cordova, Marilyn J. August, Wendy Chen, Harshvardhan B. Mehta, Kathleen L. Coelingh, Paul M. Mendelman

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

A phase 2 clinical trial was conducted to evaluate the antibody responses to bovine parainfluenza virus type 3 (bPIV3) vaccination in young infants. Three groups were tested as follows: placebo (n = 66) and 10⁵ (n = 64) or 10⁶ (n = 62) TCID₅₀ of bPIV3. The vaccine or placebo was administered intranasally at ages 2, 4, 6, and 12-15 months, and serum specimens were collected at ages 2, 6, 7, 12-15, and 13-16 months. Serum hemagglutination inhibition (HI) and IgA antibody titers against bPIV3 and human PIV3 (hPIV3) were measured. The results indicate that antibody responses to bPIV3 vaccination are more likely to be detected by the bPIV3 IgA and HI assays than by the hPIV3 IgA and HI assays, that bPIV3-induced antibody response can be differentiated from hPIV3-induced antibody response most reliably by comparing bPIV3 and hPIV3 HI titers, and that bPIV3 vaccine prevents vaccine recipients from developing antibody profiles of hPIV3 primary infection.

Original language	English
Pages (from-to)	909-913
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	184
Issue number	7
DOIs	https://doi.org/10.1086/323150
State	Published - 1 Oct 2001
Externally published	Yes

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1086/323150

Cite this

Lee, M. S., Greenberg, D. P., Yeh, S. H., Yogev, R., Reisinger, K. S., Ward, J. I., Blatter, M. M., Cho, I., Holmes, S. J., Cordova, J. M., August, M. J., Chen, W., Mehta, H. B., Coelingh, K. L., & Mendelman, P. M. (2001). Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants. Journal of Infectious Diseases, 184(7), 909-913. https://doi.org/10.1086/323150

@article{0bd6af8eb8a644e1b6f0489da15dba04,

title = "Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants",

abstract = "A phase 2 clinical trial was conducted to evaluate the antibody responses to bovine parainfluenza virus type 3 (bPIV3) vaccination in young infants. Three groups were tested as follows: placebo (n = 66) and 105 (n = 64) or 106 (n = 62) TCID50 of bPIV3. The vaccine or placebo was administered intranasally at ages 2, 4, 6, and 12-15 months, and serum specimens were collected at ages 2, 6, 7, 12-15, and 13-16 months. Serum hemagglutination inhibition (HI) and IgA antibody titers against bPIV3 and human PIV3 (hPIV3) were measured. The results indicate that antibody responses to bPIV3 vaccination are more likely to be detected by the bPIV3 IgA and HI assays than by the hPIV3 IgA and HI assays, that bPIV3-induced antibody response can be differentiated from hPIV3-induced antibody response most reliably by comparing bPIV3 and hPIV3 HI titers, and that bPIV3 vaccine prevents vaccine recipients from developing antibody profiles of hPIV3 primary infection.",

author = "Lee, {Min Shi} and Greenberg, {David P.} and Yeh, {Sylvia H.} and Ram Yogev and Reisinger, {Keith S.} and Ward, {Joel I.} and Blatter, {Mark M.} and Iksung Cho and Holmes, {Sandra J.} and Cordova, {Julie M.} and August, {Marilyn J.} and Wendy Chen and Mehta, {Harshvardhan B.} and Coelingh, {Kathleen L.} and Mendelman, {Paul M.}",

year = "2001",

month = oct,

day = "1",

doi = "10.1086/323150",

language = "English",

volume = "184",

pages = "909--913",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "7",

}

Lee, MS, Greenberg, DP, Yeh, SH, Yogev, R, Reisinger, KS, Ward, JI, Blatter, MM, Cho, I, Holmes, SJ, Cordova, JM, August, MJ, Chen, W, Mehta, HB, Coelingh, KL & Mendelman, PM 2001, 'Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants', Journal of Infectious Diseases, vol. 184, no. 7, pp. 909-913. https://doi.org/10.1086/323150

TY - JOUR

T1 - Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants

AU - Lee, Min Shi

AU - Greenberg, David P.

AU - Yeh, Sylvia H.

AU - Yogev, Ram

AU - Reisinger, Keith S.

AU - Ward, Joel I.

AU - Blatter, Mark M.

AU - Cho, Iksung

AU - Holmes, Sandra J.

AU - Cordova, Julie M.

AU - August, Marilyn J.

AU - Chen, Wendy

AU - Mehta, Harshvardhan B.

AU - Coelingh, Kathleen L.

AU - Mendelman, Paul M.

PY - 2001/10/1

Y1 - 2001/10/1

N2 - A phase 2 clinical trial was conducted to evaluate the antibody responses to bovine parainfluenza virus type 3 (bPIV3) vaccination in young infants. Three groups were tested as follows: placebo (n = 66) and 105 (n = 64) or 106 (n = 62) TCID50 of bPIV3. The vaccine or placebo was administered intranasally at ages 2, 4, 6, and 12-15 months, and serum specimens were collected at ages 2, 6, 7, 12-15, and 13-16 months. Serum hemagglutination inhibition (HI) and IgA antibody titers against bPIV3 and human PIV3 (hPIV3) were measured. The results indicate that antibody responses to bPIV3 vaccination are more likely to be detected by the bPIV3 IgA and HI assays than by the hPIV3 IgA and HI assays, that bPIV3-induced antibody response can be differentiated from hPIV3-induced antibody response most reliably by comparing bPIV3 and hPIV3 HI titers, and that bPIV3 vaccine prevents vaccine recipients from developing antibody profiles of hPIV3 primary infection.

AB - A phase 2 clinical trial was conducted to evaluate the antibody responses to bovine parainfluenza virus type 3 (bPIV3) vaccination in young infants. Three groups were tested as follows: placebo (n = 66) and 105 (n = 64) or 106 (n = 62) TCID50 of bPIV3. The vaccine or placebo was administered intranasally at ages 2, 4, 6, and 12-15 months, and serum specimens were collected at ages 2, 6, 7, 12-15, and 13-16 months. Serum hemagglutination inhibition (HI) and IgA antibody titers against bPIV3 and human PIV3 (hPIV3) were measured. The results indicate that antibody responses to bPIV3 vaccination are more likely to be detected by the bPIV3 IgA and HI assays than by the hPIV3 IgA and HI assays, that bPIV3-induced antibody response can be differentiated from hPIV3-induced antibody response most reliably by comparing bPIV3 and hPIV3 HI titers, and that bPIV3 vaccine prevents vaccine recipients from developing antibody profiles of hPIV3 primary infection.

UR - http://www.scopus.com/inward/record.url?scp=0035479189&partnerID=8YFLogxK

U2 - 10.1086/323150

DO - 10.1086/323150

M3 - Article

AN - SCOPUS:0035479189

SN - 0022-1899

VL - 184

SP - 909

EP - 913

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 7

ER -

Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this